Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers
Abstract Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emerg...
Gespeichert in:
| Veröffentlicht in: | Journal of animal science 2020-06, Vol.98 (6), p.1-6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6 |
|---|---|
| container_issue | 6 |
| container_start_page | 1 |
| container_title | Journal of animal science |
| container_volume | 98 |
| creator | Curtis, Andrew K Reif, Kathryn E Kleinhenz, Michael D Martin, Miriam S Skinner, Brandt Kelly, Sean M Jones, Douglas E Schaut, Robert G Reppert, Emily J Montgomery, Shawnee R Narasimhan, Balaji Anantatat, Tippawan Jaberi-Douraki, Majid Coetzee, Johann F |
| description | Abstract
Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emergence of antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major impediment to implementing anaplasmosis control programs. The primary objective of this study was to develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against anaplasmosis infections. Twelve Holstein steers, aged 11 to 12 wk, were administered a novel 3-stage, single-dose vaccine against Anaplasma marginale, a major surface protein 1a. The vaccine consisted of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune response, and an immune-isolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the ear. Six calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing a combination of 2 different adjuvants, diethylaminoethyl (DEAE)-Dextran and Quil-A (Group A). The remaining 6 calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). Twenty-one months post-implantation, calves were challenged intravenously with A. marginale stabilate and were monitored weekly for signs of fever, decreased packed cell volume (PCV) and bacteremia. Data were analyzed using a mixed-effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC). Calves in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection. Calves in Group A were less likely to require antibiotic intervention compared with calves in Group B (P = 0.014). Results indicate that calves exhibited diminished clinical signs of anaplasmosis when antigen was delivered with a combination of adjuvants as opposed to a single adjuvant. This demonstrates the feasibility of providing long-lasting protection against clinical bovine anaplasmosis infections using a subcutaneous ear implant vaccine construct. |
| doi_str_mv | 10.1093/jas/skz392 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7271671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jas/skz392</oup_id><sourcerecordid>2425621957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-d8f9ba03588ea1931ad7b87534c57384eabe20ce0c61180e0c01fc3924ae6a653</originalsourceid><addsrcrecordid>eNp9kV-L1TAQxYMo7vXqix9AArIgQnczSdukL4LsHxUWfNE3IUxzp5pr29SkvbB-erN2XdSHhcBA5sfhnDmMPQdxAqJRp3tMp-n7T9XIB2wDlawKBbV6yDZCSCiMAXnEnqS0FwJk1VSP2ZECYxrQesO-nNOB-jANNM48dBx5Wlq3zDhSWBInjNwPU495Owe-o94fKHIc88P8nYaQfOIHdM6P9BtBH695moliesoeddgnenY7t-zz5cWns_fF1cd3H87eXhWuVPVc7EzXtChUZQwhNApwp1ujK1W6SitTErYkhSPhagAj8hTQuRy3RKqxrtSWvVl1p6UdaOdyloi9naIfMF7bgN7-uxn9N_s1HKyWGmoNWeDVrUAMPxZKsx18ctT36xmsVDcXVRpkRl_-h-7DEsccz8pSVrWEJpvestcr5WJIKVJ3ZwaEvSnN5tLsWlqGX_xt_w7901IGjlcgLNN9Qr8AM26hrw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425621957</pqid></control><display><type>article</type><title>Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Curtis, Andrew K ; Reif, Kathryn E ; Kleinhenz, Michael D ; Martin, Miriam S ; Skinner, Brandt ; Kelly, Sean M ; Jones, Douglas E ; Schaut, Robert G ; Reppert, Emily J ; Montgomery, Shawnee R ; Narasimhan, Balaji ; Anantatat, Tippawan ; Jaberi-Douraki, Majid ; Coetzee, Johann F</creator><creatorcontrib>Curtis, Andrew K ; Reif, Kathryn E ; Kleinhenz, Michael D ; Martin, Miriam S ; Skinner, Brandt ; Kelly, Sean M ; Jones, Douglas E ; Schaut, Robert G ; Reppert, Emily J ; Montgomery, Shawnee R ; Narasimhan, Balaji ; Anantatat, Tippawan ; Jaberi-Douraki, Majid ; Coetzee, Johann F</creatorcontrib><description>Abstract
Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emergence of antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major impediment to implementing anaplasmosis control programs. The primary objective of this study was to develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against anaplasmosis infections. Twelve Holstein steers, aged 11 to 12 wk, were administered a novel 3-stage, single-dose vaccine against Anaplasma marginale, a major surface protein 1a. The vaccine consisted of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune response, and an immune-isolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the ear. Six calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing a combination of 2 different adjuvants, diethylaminoethyl (DEAE)-Dextran and Quil-A (Group A). The remaining 6 calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). Twenty-one months post-implantation, calves were challenged intravenously with A. marginale stabilate and were monitored weekly for signs of fever, decreased packed cell volume (PCV) and bacteremia. Data were analyzed using a mixed-effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC). Calves in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection. Calves in Group A were less likely to require antibiotic intervention compared with calves in Group B (P = 0.014). Results indicate that calves exhibited diminished clinical signs of anaplasmosis when antigen was delivered with a combination of adjuvants as opposed to a single adjuvant. This demonstrates the feasibility of providing long-lasting protection against clinical bovine anaplasmosis infections using a subcutaneous ear implant vaccine construct.</description><identifier>ISSN: 0021-8812</identifier><identifier>EISSN: 1525-3163</identifier><identifier>DOI: 10.1093/jas/skz392</identifier><identifier>PMID: 31889177</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Active control ; Adjuvants ; Anaplasma marginale ; Anaplasmosis ; Anaplasmosis - immunology ; Anaplasmosis - microbiology ; Anaplasmosis - prevention & control ; Animals ; Antibiotics ; Antigens ; Antimicrobial resistance ; Bacteremia ; Bacterial Vaccines - administration & dosage ; Bacterial Vaccines - immunology ; Biodegradability ; Biodegradation ; Calves ; Cattle ; Cattle Diseases - prevention & control ; Cell size ; Chlortetracycline ; Control programs ; Delayed-Action Preparations ; Dextran ; Diethylaminoethyl dextran ; Disease transmission ; Drug delivery systems ; Drug Implants ; Ear ; Fever ; Health risks ; Human papillomavirus ; Immune response ; Immune system ; Immunization ; Implantation ; Implants ; Infections ; Male ; Medicated feeds ; Polyanhydrides ; Priming ; Rapid Communication ; Rods ; Studies ; Vaccines</subject><ispartof>Journal of animal science, 2020-06, Vol.98 (6), p.1-6</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the American Society of Animal Science. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the American Society of Animal Science.</rights><rights>Copyright Oxford University Press Jun 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-d8f9ba03588ea1931ad7b87534c57384eabe20ce0c61180e0c01fc3924ae6a653</citedby><cites>FETCH-LOGICAL-c436t-d8f9ba03588ea1931ad7b87534c57384eabe20ce0c61180e0c01fc3924ae6a653</cites><orcidid>0000-0003-1802-3991 ; 0000-0001-9453-3657</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271671/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271671/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1578,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31889177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Curtis, Andrew K</creatorcontrib><creatorcontrib>Reif, Kathryn E</creatorcontrib><creatorcontrib>Kleinhenz, Michael D</creatorcontrib><creatorcontrib>Martin, Miriam S</creatorcontrib><creatorcontrib>Skinner, Brandt</creatorcontrib><creatorcontrib>Kelly, Sean M</creatorcontrib><creatorcontrib>Jones, Douglas E</creatorcontrib><creatorcontrib>Schaut, Robert G</creatorcontrib><creatorcontrib>Reppert, Emily J</creatorcontrib><creatorcontrib>Montgomery, Shawnee R</creatorcontrib><creatorcontrib>Narasimhan, Balaji</creatorcontrib><creatorcontrib>Anantatat, Tippawan</creatorcontrib><creatorcontrib>Jaberi-Douraki, Majid</creatorcontrib><creatorcontrib>Coetzee, Johann F</creatorcontrib><title>Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers</title><title>Journal of animal science</title><addtitle>J Anim Sci</addtitle><description>Abstract
Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emergence of antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major impediment to implementing anaplasmosis control programs. The primary objective of this study was to develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against anaplasmosis infections. Twelve Holstein steers, aged 11 to 12 wk, were administered a novel 3-stage, single-dose vaccine against Anaplasma marginale, a major surface protein 1a. The vaccine consisted of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune response, and an immune-isolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the ear. Six calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing a combination of 2 different adjuvants, diethylaminoethyl (DEAE)-Dextran and Quil-A (Group A). The remaining 6 calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). Twenty-one months post-implantation, calves were challenged intravenously with A. marginale stabilate and were monitored weekly for signs of fever, decreased packed cell volume (PCV) and bacteremia. Data were analyzed using a mixed-effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC). Calves in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection. Calves in Group A were less likely to require antibiotic intervention compared with calves in Group B (P = 0.014). Results indicate that calves exhibited diminished clinical signs of anaplasmosis when antigen was delivered with a combination of adjuvants as opposed to a single adjuvant. This demonstrates the feasibility of providing long-lasting protection against clinical bovine anaplasmosis infections using a subcutaneous ear implant vaccine construct.</description><subject>Active control</subject><subject>Adjuvants</subject><subject>Anaplasma marginale</subject><subject>Anaplasmosis</subject><subject>Anaplasmosis - immunology</subject><subject>Anaplasmosis - microbiology</subject><subject>Anaplasmosis - prevention & control</subject><subject>Animals</subject><subject>Antibiotics</subject><subject>Antigens</subject><subject>Antimicrobial resistance</subject><subject>Bacteremia</subject><subject>Bacterial Vaccines - administration & dosage</subject><subject>Bacterial Vaccines - immunology</subject><subject>Biodegradability</subject><subject>Biodegradation</subject><subject>Calves</subject><subject>Cattle</subject><subject>Cattle Diseases - prevention & control</subject><subject>Cell size</subject><subject>Chlortetracycline</subject><subject>Control programs</subject><subject>Delayed-Action Preparations</subject><subject>Dextran</subject><subject>Diethylaminoethyl dextran</subject><subject>Disease transmission</subject><subject>Drug delivery systems</subject><subject>Drug Implants</subject><subject>Ear</subject><subject>Fever</subject><subject>Health risks</subject><subject>Human papillomavirus</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Implantation</subject><subject>Implants</subject><subject>Infections</subject><subject>Male</subject><subject>Medicated feeds</subject><subject>Polyanhydrides</subject><subject>Priming</subject><subject>Rapid Communication</subject><subject>Rods</subject><subject>Studies</subject><subject>Vaccines</subject><issn>0021-8812</issn><issn>1525-3163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV-L1TAQxYMo7vXqix9AArIgQnczSdukL4LsHxUWfNE3IUxzp5pr29SkvbB-erN2XdSHhcBA5sfhnDmMPQdxAqJRp3tMp-n7T9XIB2wDlawKBbV6yDZCSCiMAXnEnqS0FwJk1VSP2ZECYxrQesO-nNOB-jANNM48dBx5Wlq3zDhSWBInjNwPU495Owe-o94fKHIc88P8nYaQfOIHdM6P9BtBH695moliesoeddgnenY7t-zz5cWns_fF1cd3H87eXhWuVPVc7EzXtChUZQwhNApwp1ujK1W6SitTErYkhSPhagAj8hTQuRy3RKqxrtSWvVl1p6UdaOdyloi9naIfMF7bgN7-uxn9N_s1HKyWGmoNWeDVrUAMPxZKsx18ctT36xmsVDcXVRpkRl_-h-7DEsccz8pSVrWEJpvestcr5WJIKVJ3ZwaEvSnN5tLsWlqGX_xt_w7901IGjlcgLNN9Qr8AM26hrw</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Curtis, Andrew K</creator><creator>Reif, Kathryn E</creator><creator>Kleinhenz, Michael D</creator><creator>Martin, Miriam S</creator><creator>Skinner, Brandt</creator><creator>Kelly, Sean M</creator><creator>Jones, Douglas E</creator><creator>Schaut, Robert G</creator><creator>Reppert, Emily J</creator><creator>Montgomery, Shawnee R</creator><creator>Narasimhan, Balaji</creator><creator>Anantatat, Tippawan</creator><creator>Jaberi-Douraki, Majid</creator><creator>Coetzee, Johann F</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RQ</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>U9A</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1802-3991</orcidid><orcidid>https://orcid.org/0000-0001-9453-3657</orcidid></search><sort><creationdate>20200601</creationdate><title>Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers</title><author>Curtis, Andrew K ; Reif, Kathryn E ; Kleinhenz, Michael D ; Martin, Miriam S ; Skinner, Brandt ; Kelly, Sean M ; Jones, Douglas E ; Schaut, Robert G ; Reppert, Emily J ; Montgomery, Shawnee R ; Narasimhan, Balaji ; Anantatat, Tippawan ; Jaberi-Douraki, Majid ; Coetzee, Johann F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-d8f9ba03588ea1931ad7b87534c57384eabe20ce0c61180e0c01fc3924ae6a653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Active control</topic><topic>Adjuvants</topic><topic>Anaplasma marginale</topic><topic>Anaplasmosis</topic><topic>Anaplasmosis - immunology</topic><topic>Anaplasmosis - microbiology</topic><topic>Anaplasmosis - prevention & control</topic><topic>Animals</topic><topic>Antibiotics</topic><topic>Antigens</topic><topic>Antimicrobial resistance</topic><topic>Bacteremia</topic><topic>Bacterial Vaccines - administration & dosage</topic><topic>Bacterial Vaccines - immunology</topic><topic>Biodegradability</topic><topic>Biodegradation</topic><topic>Calves</topic><topic>Cattle</topic><topic>Cattle Diseases - prevention & control</topic><topic>Cell size</topic><topic>Chlortetracycline</topic><topic>Control programs</topic><topic>Delayed-Action Preparations</topic><topic>Dextran</topic><topic>Diethylaminoethyl dextran</topic><topic>Disease transmission</topic><topic>Drug delivery systems</topic><topic>Drug Implants</topic><topic>Ear</topic><topic>Fever</topic><topic>Health risks</topic><topic>Human papillomavirus</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Implantation</topic><topic>Implants</topic><topic>Infections</topic><topic>Male</topic><topic>Medicated feeds</topic><topic>Polyanhydrides</topic><topic>Priming</topic><topic>Rapid Communication</topic><topic>Rods</topic><topic>Studies</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Curtis, Andrew K</creatorcontrib><creatorcontrib>Reif, Kathryn E</creatorcontrib><creatorcontrib>Kleinhenz, Michael D</creatorcontrib><creatorcontrib>Martin, Miriam S</creatorcontrib><creatorcontrib>Skinner, Brandt</creatorcontrib><creatorcontrib>Kelly, Sean M</creatorcontrib><creatorcontrib>Jones, Douglas E</creatorcontrib><creatorcontrib>Schaut, Robert G</creatorcontrib><creatorcontrib>Reppert, Emily J</creatorcontrib><creatorcontrib>Montgomery, Shawnee R</creatorcontrib><creatorcontrib>Narasimhan, Balaji</creatorcontrib><creatorcontrib>Anantatat, Tippawan</creatorcontrib><creatorcontrib>Jaberi-Douraki, Majid</creatorcontrib><creatorcontrib>Coetzee, Johann F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Career & Technical Education Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of animal science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Curtis, Andrew K</au><au>Reif, Kathryn E</au><au>Kleinhenz, Michael D</au><au>Martin, Miriam S</au><au>Skinner, Brandt</au><au>Kelly, Sean M</au><au>Jones, Douglas E</au><au>Schaut, Robert G</au><au>Reppert, Emily J</au><au>Montgomery, Shawnee R</au><au>Narasimhan, Balaji</au><au>Anantatat, Tippawan</au><au>Jaberi-Douraki, Majid</au><au>Coetzee, Johann F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers</atitle><jtitle>Journal of animal science</jtitle><addtitle>J Anim Sci</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>98</volume><issue>6</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>0021-8812</issn><eissn>1525-3163</eissn><abstract>Abstract
Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active anaplasmosis infections during the vector season has raised concerns about the potential emergence of antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major impediment to implementing anaplasmosis control programs. The primary objective of this study was to develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against anaplasmosis infections. Twelve Holstein steers, aged 11 to 12 wk, were administered a novel 3-stage, single-dose vaccine against Anaplasma marginale, a major surface protein 1a. The vaccine consisted of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune response, and an immune-isolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the ear. Six calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing a combination of 2 different adjuvants, diethylaminoethyl (DEAE)-Dextran and Quil-A (Group A). The remaining 6 calves were randomly assigned to 2 vaccine constructs (n = 3) that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). Twenty-one months post-implantation, calves were challenged intravenously with A. marginale stabilate and were monitored weekly for signs of fever, decreased packed cell volume (PCV) and bacteremia. Data were analyzed using a mixed-effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC). Calves in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection. Calves in Group A were less likely to require antibiotic intervention compared with calves in Group B (P = 0.014). Results indicate that calves exhibited diminished clinical signs of anaplasmosis when antigen was delivered with a combination of adjuvants as opposed to a single adjuvant. This demonstrates the feasibility of providing long-lasting protection against clinical bovine anaplasmosis infections using a subcutaneous ear implant vaccine construct.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>31889177</pmid><doi>10.1093/jas/skz392</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1802-3991</orcidid><orcidid>https://orcid.org/0000-0001-9453-3657</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-8812 |
| ispartof | Journal of animal science, 2020-06, Vol.98 (6), p.1-6 |
| issn | 0021-8812 1525-3163 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7271671 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Active control Adjuvants Anaplasma marginale Anaplasmosis Anaplasmosis - immunology Anaplasmosis - microbiology Anaplasmosis - prevention & control Animals Antibiotics Antigens Antimicrobial resistance Bacteremia Bacterial Vaccines - administration & dosage Bacterial Vaccines - immunology Biodegradability Biodegradation Calves Cattle Cattle Diseases - prevention & control Cell size Chlortetracycline Control programs Delayed-Action Preparations Dextran Diethylaminoethyl dextran Disease transmission Drug delivery systems Drug Implants Ear Fever Health risks Human papillomavirus Immune response Immune system Immunization Implantation Implants Infections Male Medicated feeds Polyanhydrides Priming Rapid Communication Rods Studies Vaccines |
| title | Development of a subcutaneous ear implant to deliver an anaplasmosis vaccine to dairy steers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A26%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20subcutaneous%20ear%20implant%20to%20deliver%20an%20anaplasmosis%20vaccine%20to%20dairy%20steers&rft.jtitle=Journal%20of%20animal%20science&rft.au=Curtis,%20Andrew%20K&rft.date=2020-06-01&rft.volume=98&rft.issue=6&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=0021-8812&rft.eissn=1525-3163&rft_id=info:doi/10.1093/jas/skz392&rft_dat=%3Cproquest_pubme%3E2425621957%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425621957&rft_id=info:pmid/31889177&rft_oup_id=10.1093/jas/skz392&rfr_iscdi=true |